Bristol-Myers Squibb Company today announced that the U.S. Food and Drug Administration has granted the investigational PD-1 immune checkpoint inhibitor nivolumab Breakthrough Therapy Designation for the treatment of patients with Hodgkin lymphoma after failure of autologous stem cell transplant and brentuximab.
http://ift.tt/1stUeCj
http://ift.tt/1stUeCj
No comments:
Post a Comment